Human immunodeficiency virus and heparan sulfate: From attachment to entry inhibition

Frontiers in Immunology

Volumn 4, Issue NOV, 2013, Pages

  Connell, Bridgette J ^a,b,c   Lortat Jacob, Hugues ^a,b,c  

^a UNIV GRENOBLE ALPES   (France)

^b CNRS   (France)

^c INSTITUT DE BIOLOGIE STRUCTURALE   (France)

Author keywords

Attachment and entry inhibition; CCR5 CXCR4; Co receptor binding site; Glycosaminoglycan; Gp120; Heparan sulfate; HIV 1; V3 loop

Indexed keywords

EID: 84890320471     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00385     Document Type: Review

References (104)

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 220:868-71. doi: 10.1126/science.6189183
2. Weiss RA. HIV receptors and cellular tropism. IUBMB Life (2002) 53:201-5. doi:10.1080/15216540212652
3. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med (2012) 2(11):a006965. doi:10.1101/cshperspect.a006965
4. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 17:657-700. doi:10.1146/annurev.immunol.17.1.657
5. Ugolini S, Mondor I, Sattentau QJ. HIV-1 attachment: another look. Trends Microbiol (1999) 7:144-9. doi:10.1016/S0966-842X(99)01474-2
6. Bomsel M, Alfsen A. Entry of viruses through the epithelial barrier: pathogenic trickery. Nat Rev Mol Cell Biol (2003) 4:57-68. doi:10.1038/nrm1005
7. Saidi H, Magri G, Nasreddine N, Requena M, Belec L. R5-and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: implication for mechanisms of sexual transmission. Virology (2007) 358:55-68. doi:10.1016/j.virol.2006.07.029
8. Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol (2011) 3(7):a004952. doi:10.1101/cshperspect.a004952
9. Lindahl U, Li JP. Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol (2009) 276:105-59. doi:10.1016/S1937-6448(09)76003-4
10. Lortat-Jacob H. The molecular basis and functional implications of chemokine interactions with heparan sulphate. Curr Opin Struct Biol (2009) 19:543-8. doi:10.1016/j.sbi.2009.09.003
11. Salanga CL, Handel TM. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp Cell Res (2011) 317:590-601. doi:10.1016/j.yexcr.2011.01.004
12. Rueda P, Richart A, Recalde A, Gasse P, Vilar J, Guerin C, et al. Homeostatic and tissue reparation defaults in mice carrying selective genetic invalidation of CXCL12/proteoglycan interactions. Circulation (2012) 126:1882-95. doi:10.1161/CIRCULATIONAHA.112.113290
13. Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol (2013) 14:166-80. doi:10.1038/nrm3528
14. Lortat-Jacob H, Baltzer F, Grimaud JA. Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its carboxyl-terminal sequence. J Biol Chem (1996) 271:16139-43. doi:10.1074/jbc.271.27.16139
15. Whisstock JC, Pike RN, Jin L, Skinner R, Pei XY, Carrell RW, et al. Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparindagger. J Mol Biol (2000) 301:1287-305. doi:10.1006/jmbi.2000.3982
16. Duchesne L, Octeau V, Bearon RN, Beckett A, Prior IA, Lounis B, et al. Transport of fibroblast growth factor 2 in the pericellular matrix is controlled by the spatial distribution of its binding sites in heparan sulfate. PLoS Biol (2012) 10:e1001361. doi:10.1371/journal.pbio.1001361
17. Qu X, Pan Y, Carbe C, Powers A, Grobe K, Zhang X. Glycosaminoglycan-dependent restriction of FGF diffusion is necessary for lacrimal gland development. Development (2012) 139:2730-9. doi:10.1242/dev.079236
18. Sarris M, Masson JB, Maurin D, Aa LM, Boudinot P, Lortat-Jacob H, et al. Inflammatory chemokines direct and restrict leukocyte migration within live tissues as glycan-bound gradients. Curr Biol (2012) 22:2375-82. doi:10.1016/j.cub.2012.11.018
19. Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des (2008) 72:455-82. doi:10.1111/j.1747-0285.2008.00741.x
20. Kreuger J, Kjellen L. Heparan sulfate biosynthesis: regulation and variability. J Histochem Cytochem (2012) 60:898-907. doi:10.1369/0022155412464972
21. Sadir R, Imberty A, Baleux F, Lortat-Jacob H. Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J Biol Chem (2004) 279:43854-60. doi:10.1074/jbc.M405392200
22. Spillmann D. Heparan sulfate: anchor for viral intruders? Biochimie (2001) 83:811-7. doi:10.1016/S0300-9084(01)01290-1
23. Liu J, Thorp SC. Cell surface heparan sulfate and its roles in assisting viral infections. Med Res Rev (2002) 22:1-25. doi:10.1002/med.1026
24. Vives RR, Lortat-Jacob H, Fender P. Heparan sulphate proteoglycans and viral vectors: ally or foe? Curr Gene Ther (2006) 6:35-44. doi:10.2174/156652306775515565
25. Bartlett AH, Park PW. Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications. Expert Rev Mol Med (2010) 12:e5. doi:10.1017/S1462399409001367
26. Tiwari V, Maus E, Sigar IM, Ramsey KH, Shukla D. Role of heparan sulfate in sexually transmitted infections. Glycobiology (2012) 22:1402-12. doi:10.1093/glycob/cws106
27. Kobayashi K, Kato K, Sugi T, Takemae H, Pandey K, Gong H, et al. Plasmodium falciparum BAEBL binds to heparan sulfate proteoglycans on the human erythrocyte surface. J Biol Chem (2010) 285:1716-25. doi:10.1074/jbc.M109.021576
28. Bucior I, Pielage JF, Engel JN. Pseudomonas aeruginosa pili and flagella mediate distinct binding and signaling events at the apical and basolateral surface of airway epithelium. PLoS Pathog (2012) 8:e1002616. doi:10.1371/journal.ppat.1002616
29. Norman MU, Moriarty TJ, Dresser AR, Millen B, Kubes P, Chaconas G. Molecular mechanisms involved in vascular interactions of the Lyme disease pathogen in a living host. PLoS Pathog (2008) 4:e1000169. doi:10.1371/journal.ppat.1000169
30. Lebrun P, Raze D, Fritzinger B, Wieruszeski JM, Biet F, Dose A, et al. Differential contribution of the repeats to heparin binding of HBHA, a major adhesin of Mycobacterium tuberculosis. PLoS One (2012) 7:e32421. doi:10.1371/journal.pone.0032421
31. Sureau C, Salisse J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology (2013) 57:985-94. doi:10.1002/hep.26125
32. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, et al. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol (2002) 68:206-15. doi:10.1002/jmv.10196
33. Lamas Longarela O, Schmidt TT, Schoneweis K, Romeo R, Wedemeyer H, Urban S, et al. Proteoglycans act as cellular hepatitis delta virus attachment receptors. PLoS One (2013) 8:e58340. doi:10.1371/journal.pone.0058340
34. Kalia M, Chandra V, Rahman SA, Sehgal D, Jameel S. Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. J Virol (2009) 83:12714-24. doi:10.1128/JVI.00717-09
35. Cruz L, Meyers C. Differential dependence on host cell glycosaminoglycans for infection of epithelial cells by high-risk HPV types. PLoS One (2013) 8:e68379. doi:10.1371/journal.pone.0068379
36. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, et al. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 99:13-22. doi:10.1016/S0092-8674(00)80058-6
37. Lambert S, Bouttier M, Vassy R, Seigneuret M, Petrow-Sadowski C, Janvier S, et al. HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165. Blood (2009) 113:5176-85. doi:10.1182/blood-2008-04-150342
38. Patel M, Yanagishita M, Roderiquez G, Bou-Habib DC, Oravecz T, Hascall VC, et al. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res Hum Retroviruses (1993) 9:167-74. doi:10.1089/aid.1993.9.167
39. Urbinati C, Chiodelli P, Rusnati M. Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules (2008) 13:2758-85. doi:10.3390/molecules13112758
40. Walker SJ, Pizzato M, Takeuchi Y, Devereux S. Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection. J Virol (2002) 76:6909-18. doi:10.1128/JVI.76.14.6909-6918.2002
41. Lee E, Pavy M, Young N, Freeman C, Lobigs M. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res (2006) 69:31-8. doi:10.1016/j.antiviral.2005.08.006
42. Basu A, Kanda T, Beyene A, Saito K, Meyer K, Ray R. Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J Virol (2007) 81:3933-41. doi:10.1128/JVI.02622-06
43. Klimstra WB, Ryman KD, Johnston RE. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J Virol (1998) 72:7357-66.
44. Hulst MM, Van Gennip HG, Moormann RJ. Passage of classical swine fever virus in cultured swine kidney cells selects virus variants that bind to heparan sulfate due to a single amino acid change in envelope protein E(rns). J Virol (2000) 74:9553-61. doi:10.1128/JVI.74.20.9553-9561.2000
45. Mandl CW, Kroschewski H, Allison SL, Kofler R, Holzmann H, Meixner T, et al. Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J Virol (2001) 75:5627-37. doi:10.1128/JVI.75.12.5627-5637.2001
46. Bear JS, Byrnes AP, Griffin DE. Heparin-binding and patterns of virulence for two recombinant strains of Sindbis virus. Virology (2006) 347:183-90. doi:10.1016/j.virol.2005.11.034
47. Sherer NM, Jin J, Mothes W. Directional spread of surface-associated retroviruses regulated by differential virus-cell interactions. J Virol (2010) 84:3248-58. doi:10.1128/JVI.02155-09
48. Connolly SA, Jackson JO, Jardetzky TS, Longnecker R. Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat Rev Microbiol (2011) 9:369-81. doi:10.1038/nrmicro2548
49. Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol (2004) 6:401-10. doi:10.1111/j.1462-5822.2004.00389.x
50. Hu YP, Lin SY, Huang CY, Zulueta MM, Liu JY, Chang W, et al. Synthesis of 3-O-sulfonated heparan sulfate octasaccharides that inhibit the herpes simplex virus type 1 host-cell interaction. Nat Chem (2011) 3:557-63. doi:10.1038/nchem.1073
51. Ceballos A, Remes Lenicov F, Sabatte J, Rodriguez Rodrigues C, Cabrini M, Jancic C, et al. Spermatozoa capture HIV-1 through heparan sulfate and efficiently transmit the virus to dendritic cells. J Exp Med (2009) 206:2717-33. doi:10.1084/jem.20091579
52. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 1:25-34. doi:10.1038/nrmicro729
53. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med (1997) 3:42-7. doi:10.1038/nm0197-42
54. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 8:447-57. doi:10.1038/nri2302
55. Wu Z, Chen Z, Phillips DM. Human genital epithelial cells capture cell-free human immunodeficiency virus type 1 and transmit the virus to CD4+ Cells: implications for mechanisms of sexual transmission. J Infect Dis (2003) 188:1473-82. doi:10.1086/379248
56. Bobardt MD, Chatterji U, Selvarajah S, Van Der Schueren B, David G, Kahn B, et al. Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J Virol (2007) 81:395-405. doi:10.1128/JVI.01303-06
57. Nazli A, Kafka JK, Ferreira VH, Anipindi V, Mueller K, Osborne BJ, et al. HIV-1 gp120 induces TLR2-and TLR4-mediated innate immune activation in human female genital epithelium. J Immunol (2013) 191(8):4246-58. doi:10.4049/jimmunol.1301482
58. Kumar RB, Maher DM, Herzberg MC, Southern PJ. Expression of HIV receptors, alternate receptors and co-receptors on tonsillar epithelium: implications for HIV binding and primary oral infection. Virol J (2006) 3:25. doi:10.1186/1743-422X-3-25
59. Vidricaire G, Gauthier S, Tremblay MJ. HIV-1 infection of trophoblasts is independent of gp120/CD4 Interactions but relies on heparan sulfate proteoglycans. J Infect Dis (2007) 195:1461-71. doi:10.1086/515576
60. Bobardt MD, Saphire AC, Hung HC, Yu X, Van Der Schueren B, Zhang Z, et al. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity (2003) 18:27-39. doi:10.1016/S1074-7613(02)00504-6
61. Argyris EG, Acheampong E, Nunnari G, Mukhtar M, Williams KJ, Pomerantz RJ. Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. J Virol (2003) 77:12140-51. doi:10.1128/JVI.77.22.12140-12151.2003
62. Banks WA, Robinson SM, Wolf KM, Bess JW Jr, Arthur LO. Binding, internalization, and membrane incorporation of human immunodeficiency virus-1 at the blood-brain barrier is differentially regulated. Neuroscience (2004) 128:143-53. doi:10.1016/j.neuroscience.2004.06.021
63. Bobardt MD, Salmon P, Wang L, Esko JD, Gabuzda D, Fiala M, et al. Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J Virol (2004) 78:6567-84. doi:10.1128/JVI.78.12.6567-6584.2004
64. Poiesi C, De Francesco MA, Baronio M, Manca N. HIV-1 p17 binds heparan sulfate proteoglycans to activated CD4(+) T cells. Virus Res (2008) 132:25-32. doi:10.1016/j.virusres.2007.10.006
65. Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem (2001) 276:3254-61. doi:10.1074/jbc.M006701200
66. Greiner VJ, Shvadchak V, Fritz J, Arntz Y, Didier P, Frisch B, et al. Characterization of the mechanisms of HIV-1 Vpr(52-96) internalization in cells. Biochimie (2011) 93:1647-58. doi:10.1016/j.biochi.2011.05.033
67. Gali Y, Delezay O, Brouwers J, Addad N, Augustijns P, Bourlet T, et al. In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. Antimicrob Agents Chemother (2010) 54:5105-14. doi:10.1128/AAC.00456-10
68. Pirrone V, Wigdahl B, Krebs FC. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res (2011) 90:168-82. doi:10.1016/j.antiviral.2011.03.176
69. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1984) 312:767-8. doi:10.1038/312767a0
70. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 280:1949-53. doi:10.1126/science.280.5371.1949
71. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 393:648-59. doi:10.1038/31405
72. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature (2005) 433:834-41. doi:10.1038/nature03327
73. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, et al. Structure of a V3-containing HIV-1 gp120 core. Science (2005) 310:1025-8. doi:10.1126/science.1118398
74. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 384:179-83. doi:10.1038/384179a0
75. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switch-hitter. AIDS Res Hum Retroviruses (2005) 21:171-89. doi:10.1089/aid.2005.21.171
76. Ito M, Baba M, Sato A, Pauwels R, De Clercq E, Shigeta S. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res (1987) 7:361-7. doi:10.1016/0166-3542(87)90001-5
77. Baba M, Snoeck R, Pauwels R, De Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother (1988) 32:1742-5. doi:10.1128/AAC.32.11.1742
78. Mitsuya H, Looney DJ, Kuno S, Ueno R, Wong-Staal F, Broder S. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (1988) 240:646-9. doi:10.1126/science.2452480
79. Ohshiro Y, Murakami T, Matsuda K, Nishioka K, Yoshida K, Yamamoto N. Role of cell surface glycosaminoglycans of human T cells in human immunodeficiency virus type-1 (HIV-1) infection. Microbiol Immunol (1996) 40:827-35.
80. Rider CC, Coombe DR, Harrop HA, Hounsell EF, Bauer C, Feeney J, et al. Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry (1994) 33:6974-80. doi:10.1021/bi00188a029
81. Harrop HA, Rider CC. Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4. Glycobiology (1998) 8:131-7. doi:10.1093/glycob/8.2.131
82. Roderiquez G, Oravecz T, Yanagishita M, Bou-Habib DC, Mostowski H, Norcross MA. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol (1995) 69:2233-9.
83. Schols D, Pauwels R, Desmyter J, De Clercq E. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology (1990) 175:556-61. doi:10.1016/0042-6822(90)90440-3
84. Callahan LN, Phelan M, Mallinson M, Norcross MA. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol (1991) 65:1543-50.
85. Ibrahim J, Griffin P, Coombe DR, Rider CC, James W. Cell-surface heparan sulfate facilitates human immunodeficiency virus type 1 entry into some cell lines but not primary lymphocytes. Virus Res (1999) 60:159-69. doi:10.1016/S0168-1702(99)00018-0
86. Bartolini B, Di Caro A, Cavallaro RA, Liverani L, Mascellani G, La Rosa G, et al. Susceptibility to highly sulphated glycosaminoglycans of human immunodeficiency virus type 1 replication in peripheral blood lymphocytes and monocyte-derived macrophages cell cultures. Antiviral Res (2003) 58:139-47. doi:10.1016/S0166-3542(02)00209-7
87. Fadnes B, Husebekk A, Svineng G, Rekdal O, Yanagishita M, Kolset SO, et al. The proteoglycan repertoire of lymphoid cells. Glycoconj J (2012) 29:513-23. doi:10.1007/s10719-012-9427-9
88. Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J Virol (2001) 75:9187-200. doi:10.1128/JVI.75.19.9187-9200.2001
89. Saidi H, Magri G, Carbonneil C, Bouhlal H, Hocini H, Belec L. Apical interactions of HIV type 1 with polarized HEC-1 cell monolayer modulate R5-HIV type 1 spread by submucosal macrophages. AIDS Res Hum Retroviruses (2009) 25:497-509. doi:10.1089/aid.2008.0156
90. Jones KS, Petrow-Sadowski C, Bertolette DC, Huang Y, Ruscetti FW. Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. J Virol (2005) 79:12692-702. doi:10.1128/JVI.79.20.12692-12702.2005
91. Batinic D, Robey FA. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem (1992) 267:6664-71.
92. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol (2000) 74:1948-60. doi:10.1128/JVI.74.4.1948-1960.2000
93. Flexner C, Barditch-Crovo PA, Kornhauser DM, Farzadegan H, Nerhood LJ, Chaisson RE, et al. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother (1991) 35:2544-50. doi:10.1128/AAC.35.12.2544
94. Vives RR, Crublet E, Andrieu JP, Gagnon J, Rousselle P, Lortat-Jacob H. A novel strategy for defining critical amino acid residues involved in protein/glycosaminoglycan interactions. J Biol Chem (2004) 279:54327-33. doi:10.1074/jbc.M409760200
95. Crublet E, Andrieu JP, Vives RR, Lortat-Jacob H. The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site. J Biol Chem (2008) 283:15193-200. doi:10.1074/jbc.M800066200
96. Basmaciogullari S, Babcock GJ, Van Ryk D, Wojtowicz W, Sodroski J. Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding. J Virol (2002) 76:10791-800. doi:10.1128/JVI.76.21.10791-10800.2002
97. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 455:109-13. doi:10.1038/nature07159
98. Vives RR, Imberty A, Sattentau QJ, Lortat-Jacob H. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem (2005) 280:21353-7. doi:10.1074/jbc.M500911200
99. Baleux F, Loureiro-Morais L, Hersant Y, Clayette P, Arenzana-Seisdedos F, Bonnaffe D, et al. A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry. Nat Chem Biol (2009) 5:743-8. doi:10.1038/nchembio.207
100. Connell BJ, Baleux F, Coic YM, Clayette P, Bonnaffe D, Lortat-Jacob H. A synthetic heparan sulfate-mimetic peptide conjugated to a mini CD4 displays very high anti-HIV-1 activity independently of coreceptor usage. Chem Biol (2012) 19:131-9. doi:10.1016/j.chembiol.2011.12.009
101. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 317:1930-4. doi:10.1126/science.1145373
102. Tilton JC, Doms RW. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res (2010) 85:91-100. doi:10.1016/j.antiviral.2009.07.022
103. Mehellou Y, De Clercq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem (2010) 53:521-38. doi:10.1021/jm900492g
104. Mulloy B. Structure and physicochemical characterisation of heparin. Handb Exp Pharmacol (2012) 207:77-98. doi:10.1007/978-3-642-23056-1_5